Innovative Diagnostic Model Based on Beta-Catenin, Tumor Necrosis Factor-Alpha, Interleukin 21 and CA19.9 Biomarkers for Follow-up of HCC Development After DAA Therapy for HCV In - Egyptian Knowledge Bank

410016

Innovative Diagnostic Model Based on Beta-Catenin, Tumor Necrosis Factor-Alpha, Interleukin 21 and CA19.9 Biomarkers for Follow-up of HCC Development After DAA Therapy for HCV In

Article

Last updated: 29 Mar 2025

Overview Similar Items

Article

Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy

Article

Novel Prognostic Indicators to reflect The Grade of Liver Fibrosis in Hepatic Patients

Article

Evaluation of serum Midkine as a Diagnostic Marker for Hepatocellular Carcinoma in Hepatitis C virus Patients with Liver Cirrhosis

Article

Biochemical and Molecular Alterations of Micro RNA 125b and Micro RNA 489-3p as diseases biomarkers in Hepatitis C Virus (HCV)

Article

Interleukin 17 levels used as diagnostic marker for following up hepatitis C virus treatment

Article

EVALUATION OF DES-GAMMA CARBOXY PROTHROMBIN AS A BIOMARKER FOR EARLY DETECTION OF HEPATOCELLULAR CARCINOMA ON TOP OF CHRONIC ACTIVE HEPATITIS POST VIRUS C INFECTION

Article

Assessment of Annexin A2 as A Marker for Diagnosis of Hepatocellular Carcinoma in Compensated and Decompensated Hepatitis C Virus Treated Patients

Article

Mac-2 binding protein glycosylation isomer as a marker of hepatocellular carcinoma in patients with hepatitis C virus

Article

MOLECULAR MARKERS PREDICTING THE EFFICACY OF INTERFERON-BASED THERAPIES IN PATIENTS WITH CHRONIC HEPATITIS C

Article

Assessment of Alpha-1-Acid Glycoprotein as a new Biomarker for Hepatocellular Carcinoma